Dr. Angelo Pirozzi from Mayo Clinic in conversation with Dr. Mark Lewis from Intermountain Health
Dr. Lewis discussed the criteria for selecting between nivolumab and pembrolizumab based on PD-L1 expression levels, and how insurance considerations can influence treatment decisions. he also addressed the correlation between the efficacy and toxicity of chemoimmunotherapy, emphasizing the impoortance of patient education and awareness among healthcare providers.
Additionally, he touched on the potential for achieving sustained complete responses in advanced gasteric cancer, drawing parallels with melanoma treatment strategies. Dr. Lewis shared an inspiring anecdote from his practice, highlighting the challenges and triumphs in oncology.